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 Hepatitis C virus (HCV) infection is common among patients with opioid use disorder 
(OUD), a population who faces barriers to HCV treatment access. Co-located treatment for HCV 
within an opioid treatment program (OTP) addresses gaps in the HCV care continuum. Few 
reports have analyzed outcomes related to OUD, such as OUD treatment retention, associated 
with onsite HCV treatment. Patients (N=89) treated for chronic HCV infection in a Connecticut 
OTP from January 2014 through July 2017 were compared to control patients (N=199) with 
HCV-based ICD10 coding (B18.2) who were not treated during the same period. All patients 
received opioid agonist treatment (OAT) as part of an OTP. To assess the period following HCV 
treatment, a look-back period from September 2017 through September 2018 was included. 
Outcomes include (1) retention in OUD treatment from January 2014 through September 2018, 
analyzed first using logistic regression and subsequently using survival analysis based on OTP 
loss to follow-up dates; (2) urine analysis (UA) results screening for non-prescribed opioids 
during the look-back period, analyzed using ordered logistic regression; (3) changes in a 
behavior and symptom scale based on the BASIS-24 validated instrument, analyzed using linear 
regression. After adjusting for all baseline covariates, patients who initiated and completed HCV 
treatment had 2.2 (95% CI: 1.1, 4.5) increased likelihood of remaining in the OTP compared to 
patients in the control group. There were no differences between the two groups in terms of UA 
results of non-prescribed opioids or changes in BASIS-24 scores. Results indicate that the co-
located model of concurrent HCV and OUD treatment is associated with improved OTP 
treatment retention following HCV treatment. This naturalistic study confirms prior findings that 
co-located treatment models are feasible and effective, and suggests that this model has an 
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 In October 2018, the United States 115th Congress passed the “Substance Use Disorder 
Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and 
Communities Act.”1 This act, specifically Section 7141, included language that linked infectious 
diseases with widespread illicit drug use, and further appropriated funds for increased 
surveillance and education efforts related to infectious diseases spread through drug use.2 
Though this link is evident to practitioners who have worked at the intersection of infectious 
diseases and drug use for decades, the signal in the form of federal statute is noteworthy.  
 Hepatitis C virus (HCV) infection is a significant contributor to morbidity and mortality 
in the US. In 2012, deaths related to hepatitis C surpassed deaths related to any of 60 other 
nationally-notifiable infectious diseases reportable to the Centers for Disease Control and 
Prevention (CDC), including Human Immunodeficiency Virus (HIV).3 Though other groups are 
at risk for HCV infection, persons who use or inject drugs are often deemed the most vulnerable 
to new HCV infections, given that the infection is primarily spread through infected blood. The 
CDC estimates that injection drug use is the most common means of transmission in the US, 
despite the substantial challenges related to the classification and detection of acute and chronic 
cases.4, 5 It is increasingly recognized that rising HCV incidence is closely tied with widespread 
injection drug use.6 The American Association for the Study of Liver Disease (AASLD) and 
Infectious Diseases Society of America (ISDA) recommend ongoing testing and linkage-to-care, 
if applicable, for persons who inject drugs (PWID).7 The advent of direct acting antiviral 
treatment (DAA) revolutionized HCV treatment with decreased treatment duration, improved 
side effect profile, and greater likelihood of establishment of sustained virologic response (SVR), 
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or viral cure.8 It is well-established that it is feasible, using DAA treatment, to achieve SVR in 
PWID.9,10 
Researchers have also demonstrated that HCV treatment is effective at achieving SVR 
within 12 weeks (SVR 12) in patients who concurrently receive treatment with opioid agonist 
medications for the treatment of opioid use disorder (OUD). In a randomized control trial 
conducted across 12 countries, drug use at baseline and during treatment did not affect SVR 12 
or adherence to HCV treatment among patients receiving opioid agonist treatment (OAT).11 
Though the possibility of HCV cure among PWID who also receive OAT has been 
demonstrated, there remain barriers for this population in accessing education about the natural 
history of HCV infection, screening, and treatment. The understanding of these barriers through 
qualitative inquiry has been conducted in the pre-DAA era of HCV treatment in the Enhancing 
Treatment for Hepatitis C in the Opioid Substitution Setting (ETHOS) study in Australia, in 
which researchers noted barriers of feeling well, concerns about efficacy of treatment, family 
responsibilities, and unstable housing.12 A recent qualitative study in the post-DAA era 
interviewed 30 Australian PWID with serologic evidence of chronic HCV infection; participants 
discussed themes of lack of symptoms directly attributable to HCV infection, lack of accurate 
information about HCV treatment and treatment access, and lack of models of care that could 
support the unique needs of PWID.13 Several participants in this study specifically proposed the 
concurrent receipt of medication for OUD and HCV at their opioid treatment program (OTP) as 
a way to establish a “routine.”13 Such a solution addresses gaps in the HCV care continuum, 
obviating the need for offsite referrals for follow-up ribonucleic acid (RNA) confirmatory 
testing, treatment workup, and management of the treatment regimen at a separate location. At 
the same OTP that is the context for the present study, Butner et al. observed a 98% SVR 12 rate 
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for a small sample of patients who received concurrent OUD and HCV treatment in a co-located 
model of care.14 Another potential effective solution to addressing gaps in the HCV care 
continuum for this population is the use of telemedicine for HCV treatment within an OTP 
setting, should on-site integrated primary care services not be feasible and/or sustainable.15  
 In studies on the general effectiveness of HCV treatment among PWID and among those 
who receive treatment for OUD in the form of opioid agonists, either in a co-located model of 
treatment or not, the primary outcome of interest is most typically SVR 12. There is considerably 
less literature examining the potential effect of DAA treatment for HCV on OUD outcomes, 
most notably of retention in care in an OTP. In a six-year observational study in Taiwan, Chen et 
al. record retention in care using a time-spanning method and found that patients with OUD and 
HCV infection had better retention in care.16 Such observations are not easily transferable to the 
American medical system in which OTPs are not typically located within the psychiatric 
department of hospitals, as in Taiwan, but rather are located in the community and generally 
separate from other healthcare services. It is also critical to note that authors were looking at 
patients with HCV infection, not those patients who had been treated and cured; the study pre-
dated the approval of DAAs.16 
 
Study Objectives and Hypotheses   
 The objective of this study is to examine OUD outcomes among a population of patients 
treated with DAAs for HCV treatment while concurrently receiving OAT in a comprehensive 
OTP. I examined the association between HCV treatment and the OUD outcomes of (1) retention 
in the OTP, (2) urine analysis (UA) results screening for non-prescribed opioids, and (3) changes 
in results of a behavior and symptom scale based on the Behavior and Symptom Identification 
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Scale of 24 questions (BASIS-24) validated instrument. The primary hypothesis is that patients 
who have initiated and completed treatment for chronic HCV infection and receive co-located 
treatment for OUD will have improved retention in care in the OTP as compared to those who 
are infected with HCV but untreated and receive treatment for OUD. Secondary hypotheses are 
that patients treated for chronic HCV infection will have lesser proportions of positive urine drug 
analyses for non-prescribed opioids as well as improved scores in a behavior and symptom 
survey instrument over time compared to those who did not receive HCV treatment.  
I intend to use the data analysis to inform an existing effective model of HCV treatment 
co-located with treatment for OUD. Though this model is highly effective in curing patients with 
HCV infection and treating the chronic illness of addiction, there remain patients who are 
diagnosed with HCV yet do not receive treatment and have co-occurring substance use disorder. 
Through my analyses, I hope to identify characteristics of HCV-treated patients who are retained 
in the OTP, have lower proportions of positive UAs for non-prescribed opioids, and have 
improved scores in a behavior and symptom survey instrument. I clearly note that the goal of this 
study is not to identify characteristics of those who do or do not initiate HCV treatment itself in a 
co-located model of treatment with OUD; for such a study objective, prospective and more-
detailed data would be required. Should OUD outcomes improve among those receiving co-
located treatment for HCV, this could potentially further validate the co-located model of care 
and prompt other OTPs to incorporate HCV screening and treatment into their programs, if 
feasible. It could also add to the growing literature that patients with OUD receiving OAT should 






Study Setting  
 The APT Foundation is a not-for-profit addiction treatment program with integrated 
primary care services that serves patients at several locations in South Central Connecticut.17 A 
full description of the medical model and clinical processes for treatment of chronic HCV 
provided at APT Foundation has been described elsewhere by clinician-researchers at the 
practice.18 In brief, however, the APT Foundation provides an open access model to patients 
seeking OAT as part of a comprehensive OTP including intensive outpatient services, residential 
treatment, onsite psychiatric care, and onsite primary medical care.19 Patients treated with 
methadone or buprenorphine receive a physical and psychiatric evaluation by providers upon 
intake into the OTP, including an opt-out HCV antibody screening. Patients with positive HCV 
antibody tests are notified and receive HCV RNA confirmatory testing. If RNA confirmatory 
testing is positive, patients receive further workup for and counseling about treatment options. 
Patients are treated with DAAs under the management of APT Foundation clinicians and staff. 
Though data on patients’ insurance status are not available in this study, it is notable that in 
Connecticut, the state Medicaid program does not restrict coverage of DAAs based upon 
sobriety, specialty provider, and/or degree of fibrosis.20 For all patients who participate in the 
OTP, unique treatment plans are developed by clinicians for the daily, weekly, or monthly 
administration of methadone or buprenorphine.18 
 Upon intake to the OTP, all patients are asked to complete a BASIS-24 instrument. The 
BASIS-24 is a validated behavioral health assessment tool developed and licensed by McClean 
Hospital, a Harvard Medical School affiliate.21,22 The BASIS-24 survey results are subdivided 
into six sub-scores and one overall score. The BASIS-24 instrument also includes questions 
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related to demographic characteristics, including age, sex, marital and employment status, among 
others. Patients complete the BASIS-24 during the intake process and each year thereafter. Due 
to the possibility that patients may have multiple treatment episodes at APT Foundation, it is 
possible that patients do not have documented BASIS-24 survey results for each year of their 
participation in the program or have more than one result per year.  
 This study was approved by the Institutional Review Board of Yale University Human 
Investigation Committee and the Board of Directors at the APT Foundation. 
 
Study Design and Sample    
This study was a retrospective, observational case-control study. I chose the beginning of 
the study period at 1/1/2014 to reflect the Food and Drug Administration approval of DAAs and 
their entrance to the market beginning in late 2013 as well as patient accessibility of these 
medications.23 The cutoff date of 7/8/2017 for the selection of patients who had been treated for 
chronic HCV was arbitrary. The study’s look-back period for the secondary outcome of 
proportion of positive urine drug analyses for non-prescribed opioids was a 12-month period 
between 9/30/2017 and 9/30/2018. This gap in time from the end of the HCV treatment period 
(7/8/2017) to the beginning of the look-back period (9/30/2017) allows for the possibility that a 
patient could have completed treatment on the last day of the study period, allowing for 12 
weeks of follow-up by which to measure SVR 12.  
Patients were included in the treatment group if they initiated treatment for HCV 
infection between 1/1/2014 and 7/8/2017. All patients in the treatment group have documented 
dates of treatment completion and SVR 12 in a clinical registry of HCV-treated patients. A 
clinician at the APT Foundation provided me with this clinical registry according to the time 
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parameters I set. Patients were excluded from the treatment group if they did not receive 
concurrent OAT at the APT Foundation at the time in which they initiated HCV treatment. 
Therefore, patients who were enrolled in primary care only or primary care only at the time of 
HCV treatment initiation were excluded. Patients who received treatment for OUD at locations 
other than APT Foundation were excluded from the study.  
The lead information technology (IT) staff member at APT Foundation provided a data 
set of all patients with a documented ICD10 code for chronic viral hepatitis, B18.2, during the 
time period 1/1/2014 to 7/8/2017 who were also enrolled in the OTP. ICD 10 coding for chronic 
viral hepatitis does not differentiate between patients with chronic viremia and those who have a 
positive HCV antibody but do not have viremia. A condition for treatment with DAAs is 
documentation of chronic viremia. Using SAS Version 9.4 (SAS Institute Inc., Cary, NC) and 
with the assumption that all patients treated for chronic HCV infection have ICD10 code B18.2, I 
removed the patients in the treatment group (provided to me from the clinical registry of treated 
patients) from the ICD 10 B18.2 data set. The remaining patients became the control group of the 
study. I then excluded any patient who was enrolled only in primary care services during the 
study period. After a medical chart review of all patients in the control group, I removed patients 
who had chart documentation of treatment for HCV elsewhere and/or prior to the study period. 
 
Study Variables and Analytic Approach  
 The lead IT staff member at APT Foundation provided all BASIS-24 scores for all 
patients in the study. As patients’ demographic data was linked to their BASIS-24 survey results 
and as the date of completion was critical to the study’s aims, the BASIS-24 surveys with 
missing dates of completion, or dates of completion prior to the beginning of the study period 
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(1/1/2014), were removed from the data set. This removal of BASIS-24 survey results as 
described was completed for both the treatment and control groups. All baseline demographic 
covariates as well as behavior and symptom indicators were derived from patients’ BASIS-24 
survey result closest following the beginning of the study period (1/1/2014). 
I also received all recorded dates of loss to follow-up for all patients in the study during 
the period 1/1/2014 to 9/30/2018. Notably, this time period spans the initial study period as well 
as the study lookback period. Retention for the purpose of this study was defined as the absence 
of a recorded date of loss to follow-up during the period 1/1/2014 to 9/30/2018. Though patients 
may have had multiple episodes of treatment at the APT Foundation during this time, the present 
study was concerned only with the patients’ status in the OTP at the conclusion of the study 
period (9/30/2018). I also lack information on reasons for patient loss to follow-up. Using the 
dates of loss to follow-up, I coded retention as a binary variable, either retained at the conclusion 
of the study (9/30/2018) or not.  
 Clinical data were abstracted by comprehensive chart review of the study look-back 
period, 9/30/2017 to 9/30/2018. Prior to completing the chart review, I met with APT Foundation 
leadership, clinicians, as well as research and IT staff to develop a data dictionary of clinically-
meaningful measures. The outcome variable of proportion of positive urine drug analyses for 
non-prescribed opioids was derived through the following process: first, I examined the chart 
during the look-back period for any prescription validation documentation for synthetic opioids, 
then queried the electronic record system for all UA results during the look-back period. Patients 
typically have anywhere between 8 to 20 UAs over one year, each of which screen for 15 
analytes.24 I entered the fraction of positive UAs for opioids over the total number of UAs in an 
Excel sheet to arrive at a proportion. If a patient had a prescription validation entered into the 
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clinical chart by a master’s level clinician for a synthetic opioid at any point during the look-back 
period, positive results for opioids in the UAs were not factored into the calculation. The same 
process was completed for the proportion of positive UAs for non-prescribed benzodiazepines 
and cocaine during the study look-back period. Therefore, I did not count urine toxicology for 
prescribed opioids or benzodiazepines as positive urine toxicology analysis. Prescription 
validations for both opioids and benzodiazepines were also recorded as binary variables in the 
data abstraction. I included a documentation of the type of OAT a patient received during the 
look-back period. In addition, I included the covariate “counsel” as a patient having use of 
counseling services beyond the program’s requirement of one group or individual session per 
month at any point during the look-back period. This was meant to capture added counseling 
treatment services above and beyond usual care. The electronic medical chart system does not, 
however, capture the use of counseling services external to the OTP. I included a covariate for 
the use of psychiatric services at APT Foundation during the look-back period as evidenced by a 
documentation of a medical visit coded in psychiatric services. Lastly, I included a covariate for 
use of intensive outpatient (IOP) services during the study period as evidenced by a 
documentation of IOP services.  
 All study data were de-identified using a formula to code the patient identification 
number before conducting analyses. All data cleaning and statistical analyses were conducted in 
SAS Version 9.4. Bivariate analyses used chi-square tests for binary and categorical variables, 
and t-tests for continuous variables. Retention was analyzed first as a binary outcome variable in 
a logistic regression model, using a backward stepwise elimination strategy to arrive at the most 
parsimonious model. I conducted a subsequent Kaplan-Meier survival analysis with retention 
according to the dates of loss to follow-up. To conduct this analysis, I set a length of follow-up 
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variable as the time between the date of loss to follow-up and the date of the first BASIS-24 
survey in the study period. If a patient did not have a date of loss to follow-up, I set the censor 
date as the last day of the study period (9/30/2018). I then conducted a Cox proportional hazards 
model, though notably there was a violation of the proportional hazards assumption and this will 
be discussed in the subsequent section. The secondary outcome variable of the proportion of 
positive UAs for non-prescribed opioids was a continuous variable, ranging from 0 to 1, with 0 
meaning no positive screens and 1 meaning all positive screens during the study look-back 
period. The data, however, were more interpretable if I categorized the proportions into quartiles. 
Therefore, I conducted an ordered logistic regression with the categorized positive UA 
proportions as the outcome variable using a backward stepwise elimination strategy. I also 
completed the same categorization for the covariate of positive UA proportions for 
benzodiazepines and cocaine screens. The last outcome of interest, change in BASIS-24 scores 
over the study period, was first conducted using t-tests for each of the sub-scores and overall 
score for the “pre” and “post” period. Results closest to a score of 0 indicate less frequent 
symptoms or difficulty while a score of 4 indicates more frequent symptoms or difficulty. 
Therefore, when analyzing differences, greater negative values for differences over time would 
indicate patient improvement based on BASIS-24 scoring. As described, the initial BASIS-24 
survey date closest to 1/1/2014 was used as the “pre” results; the BASIS-24 survey date closest 
to the last day of the study period (9/30/2018) was used as the “post” result. I analyzed the 
differences first using t-tests for all sub-scores and overall score, then conducted a linear 






Description of the Sample and Bivariate Analyses  
 According to the exclusion and inclusion criteria for the treatment and control groups as 
described, there were 89 patients in the treatment group and 199 patients in the control group. 
Patients in the treatment group were an average age of 42.8 (±11.5) years at the beginning of the 
study period and were primarily non-Hispanic white males. Of the treatment group, 42.5% 
completed high school or attained a GED, 59.1% were never married, 68.2% did not report 
working in the past 30 days, and 92.1% reported not being a student in the past 30 days. Patients 
in the control group resemble patients in the treatment group according to the covariates included 
in this study. The average age of those in the control group is 43.9 (±11.9) at the beginning of the 
study period. Though the control group was also largely composed of non-Hispanic white males, 
the ratio of males to females was more balanced in the control group and there was a greater 
percent of patients who reported Hispanic race/ethnicity in the control as compared to the 
treatment group. Of the control group, 39.8% reported completing high school or attaining a 
GED, 50.5% were never married, 75.3% reported not working in the past 30 days, and 94.4% 
reported not being a student in the past 30 days. According to bivariate analyses of demographic 
characteristics included in this study, there were no significant differences between the treatment 
and control groups (Table 1). Data on the total patient population enrolled in the OTP at APT 
Foundation during this time period would be useful for comparative purposes but are not 









Table 1. Baseline demographic characteristics according to HCV treatment status using BASIS-24 
survey results closest following 1/1/2014a, b  
  HCV Treatment   
Characteristic Treatment (N = 89)  Control (N=199) Pc   
Age (years) 42.8 (±11.5) 43.9 (±11.9) 0.466 
Sex   0.107 
     Male 61 (69.3) 115 (52.3)  
     Female  27 (30.7) 79 (40.7)  
Race/Ethnicity   0.180 
     Non-Hispanic White 60 (76.9) 132 (72.1)  
     Non-Hispanic Black 9 (11.5) 12 (6.6)  
     Hispanic 7 (9.0) 27 (14.8)  
     Other 2 (2.2) 12 (6.6)  
Education    0.148 
     Some high school or less  19 (21.8) 64 (32.7)  
High school graduate/GED 37 (42.5) 78 (39.8)  
     Some college or more 31 (35.6) 54 (27.6)  
Marital status    0.356 
     Married 12 (13.6) 28 (14.1)  
Separated, divorced or widowed 24 (27.3) 70 (35.4)  
     Never married 52 (59.1) 100 (50.5)  
Employment in past 30 days   0.420 
     No 60 (68.2) 146 (75.3)  
     Yes <30 hours 16 (18.2) 25 (12.9)  
     Yes >30 hours  12 (13.6) 23 (11.9)  
Student in past 30 days   0.460 
     No 81 (92.1) 184 (94.4)  
     Yes 7 (8.0) 11 (5.6)  
a Table values are mean ± SD for continuous variables and n (column %) for categorical variables 
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to 
rounding 
c P-value is for t-test (continuous variables) or χ2 test (categorical variables 
 
 Across depression/functioning, self-harm, emotional lability, substance use, and overall 
scores, scores for the treatment group were closer to 0 than the control group, which indicates 
less frequent symptoms or difficulty. Bivariate analysis of baseline BASIS-24 survey results 
(Table 2) revealed significant differences, with the treatment group showing improved scores for 




Table 2. Baseline behavior and symptom indicators according to HCV treatment status using 
BASIS-24 survey results closest following 1/1/14a 
 HCV Treatment   
Sub-scales and overall scores Treatment (N = 89)  Control (N=199) Pb   
Depression/functioning 1.3 (± 0.9) 1.7 (± 1.1) 0.002 
Relationships 1.8 (± 1.1) 1.7 (± 1.1) 0.692 
Self-Harm 0.2 (± 0.4) 0.4 (± 0.7) 0.003 
Emotional lability 1.4 (± 0.9) 1.6 (± 1.0) 0.132 
Psychosis 0.5 (±0.7)  0.5 (± 0.8) 0.844 
Substance Abusec 1.7 (± 1.3) 1.9 (± 1.2) 0.161 
Overall  1.2 (± 0.7) 1.4 (± 0.8) 0.059 
a Table values are mean ± SD  
b P-value is for t-test 
c BASIS-24 survey instrument uses this terminology, which has been removed according to the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition (DSM-5)  
 
Results for both demographic and psychological or behavioral data were used as 
covariates for the following analyses of retention and proportion of positive urine analyses for 
non-prescribed opioids. These covariates were derived from one BASIS-24 survey administered 
and completed on a single day. 
 
Retention 
 I first began with an analysis of retention as a binary variable, either remaining in the 
OTP at the end of the study period (9/30/2018) or not, using logistic regression. In an unadjusted 
association, patients in the treatment group had 1.5 (95% confidence interval [CI], 0.9 to 2.5) 
increased likelihood of remaining in the OTP compared to patients in the control group. After 
adjusting for all covariates in the model, patients who had been treated for HCV had 2.2 (95% 
CI, 1.1 to 4.5) increased likelihood of remaining in the OTP compared to the control group, and 
this was significant at p=0.024. I then completed a backward stepwise elimination strategy to 
 
Severe 19 
find the most parsimonious model, removing gender, student status, and the BASIS-24 overall 
measure. In this model, HCV-treated patients had 2.1 (95% CI, 1.0 to 4.0) increased likelihood 
of remaining in the OTP compared with the control group and this was significant at p=0.039. 
Patient age, depression/functioning, psychosis, and substance use measures were all significant 


































Table 3. Results of logistic regression: adjusted model and best-fitting model of the association 
between retention and HCV treatment 
 Model 1  
(All variables) 
Model 2  
(Best-fitting) 
Variable OR (95% CI) p  OR (95% CI) p 
HCV treatment (Reference: 
no) 
2.2 (1.1, 4.5) 0.024 2.1 (1.0, 4.0) 0.039 
Age  1.1 (1.0, 1.1) <0.001 1.1 (1.0, 1.1) <0.001 
Sex   --  
     Female Reference -- Reference -- 
     Male  0.9 (0.5, 1.7) 0.768 -- -- 
Race/Ethnicity     
     Non-Hispanic White Reference -- Reference  -- 
     Non-Hispanic Black 1.4 (0.4, 5.6) 0.613 1.5 (0.4, 5.9) 0.526 
     Hispanic 0.8 (0.3, 2.0) 0.682 0.8 (0.3, 1.9) 0.605 
     Other 2.5 (0.7, 9.3) 0.173 2.5 (0.7, 9.4) 0.172 
Education      
    High school grad/GED Reference -- Reference -- 
    Some high school or less 0.8 (0.4, 1.6) 0.445 0.8 (0.4, 1.6) 0.507 
    Some college or more 0.5 (0.3, 1.1) 0.079 0.5 (0.3, 1.1) 0.089 
Marital status      
     Never married Reference -- Reference -- 
     Separated/divorced or  
     widowed 
0.7 (0.3, 1.5) 0.395 0.7 (0.4, 1.5) 0.401 
     Married 1.9 (0.8, 4.9) 0.171 1.9 (0.7, 4.8) 0.185 
Employment in past 30 
days 
    
     No Reference -- Reference -- 
     Yes <30 hours 2.0 (0.8, 5.2) 0.157 2.0 (0.8, 5.1) 0.150 
     Yes >30 hours  1.8 (0.7, 4.5) 0.244 1.8 (0.7, 4.6) 0.226 
Student in past 30 days 
(Reference: no)  
1.9 (0.5, 6.9) 0.341 -- -- 
Depression/Functioning 2.4 (0.6, 10.0) 0.236 1.7 (1.1, 2.7) 0.029 
Relationships 0.9 (0.5, 1.4) 0.591 0.8 (0.6, 1.1) 0.125 
Self-harm 1.2 (0.6, 2.2) 0.672 1.2 (0.7, 2.1) 0.490 
Emotional lability  1.6 (0.8, 3.0) 0.179 1.5 (1.0, 2.2) 0.073 
Psychosis 0.7 (0.4, 1.2) 0.193 0.6 (0.4, 1.0) 0.034 
Substance abusea 0.6 (0.4, 0.9) 0.006 0.6 (0.4, 0.8) <0.001 
Overall  0.5 (0.0, 10.6) 0.667 -- -- 
a BASIS-24 survey instrument uses this terminology, which has been removed according to the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition (DSM-5)  
 
 I next analyzed retention using the dates of loss to follow-up of patients in the sample. As 
noted, length of follow-up was defined as the difference between the patient’s date of loss to 
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follow-up and their first BASIS-24 survey date in the study period; if a patient did not have a 
date of loss to follow-up, the censor date was set to the last day of the study period (9/30/2018). 
Using univariate analysis, I found that the average length of follow-up for the treatment group 
was 1,114.2 (±389.2) days, while the average for the control group was 896.0 (±459.3) days. This 
is approximately 3.1 years of follow-up for the treatment group and 2.5 years for the control 
group. As these results were promising, I conducted a Kaplan-Meier survival analysis with the 
data. The survival curves indicated that the HCV treatment group had a higher probability of 
being retained over the duration of the study (1/1/14 to 9/30/18) compared with the control 
group; according to the log-rank test, the difference in the survival curves was significant at p= 
0.025 (Figure 1). 
 
Figure 1. Kaplan-Meier survival curves modeling the probability of loss to follow-up from the OTP 





 I then conducted a Cox proportional hazards regression. I first tested the time interaction 
term between the HCV treatment variable and length of follow-up; this interaction term, 
however, was significant (p=0.003), providing evidence of non-proportionality. Though the 
survival curves did not meet the statistical test for proportionality, I conducted a Cox 
proportional hazards regression as a supplemental analysis. In an unadjusted model, those who 
were treated for HCV were 0.6 (95% CI, 0.4 to 1.0) times as likely to be lost to follow-up 
compared to those in the control group; this was significant at p=0.027. I then included a model 
with all baseline covariates; in the full adjusted model, those who were treated for HCV were 0.4 
(95% CI, 0.3 to 0.7) times as likely to be lost to follow-up compared to those in the control 
group. Patient age, “other” race/ethnicity, and the BASIS-24 substance use measure were 
significant predictors in this model. Removing variables using a stepwise backward elimination 
strategy caused the hazard ratio to increase and become less statistically significant. For this 
reason, it appears that the full model provides the best-fitting model for this Cox proportional 























Table 4. Results of Cox proportional hazards regression modeling for loss to follow-up from OTP  
 Full model   
(All variables) 
Variable HR (95% CI) p  
HCV treatment (Reference: 
no) 
0.4 (0.3, 0.7) 0.001 
Age  1.0 (0.9, 1.0) <0.001 
Sex   
     Female Reference -- 
     Male  1.0 (0.6, 1.6) 0.974 
Race/Ethnicity   
     Non-Hispanic White Reference -- 
     Non-Hispanic Black 0.9 (0.3, 2.6) 0.797 
     Hispanic 1.2 (0.7, 2.2) 0.541 
     Other 0.4 (0.1, 1.0) 0.044 
Education    
    High school grad/GED Reference -- 
    Some high school or less 1.1 (0.7, 1.9) 0.669 
    Some college or more 1.5 (0.9, 2.5) 0.163 
Marital status    
     Never married Reference -- 
     Separated/divorced or  
     widowed 
1.3 (0.8, 2.3) 0.335 
     Married 0.7 (0.3, 1.3) 0.232 
Employment in past 30 
days 
  
     No Reference -- 
     Yes <30 hours 0.7 (0.3, 1.4) 0.276 
     Yes >30 hours  0.8 (0.4, 1.5) 0.411 
Student in past 30 days 
(Reference: no)  
1.0 (0.4, 2.5) 0.946 
Depression/Functioning 0.5 (0.2, 1.4) 0.200 
Relationships 1.1 (0.8, 1.6) 0.624 
Self-harm 0.9 (0.6, 1.5) 0.817 
Emotional lability  0.7 (0.4, 1.1) 0.091 
Psychosis 0.7 (0.8, 1.7) 0.490 
Substance abusea  0.6 (1.2, 2.0) 0.003 
Overall  2.0 (0.2, 18.6) 0.533 
a BASIS-24 survey instrument uses this terminology, which has been removed according to the Diagnostic 







Proportion of Positive Urine Analysis Results for Non-Prescribed Opioids  
 A description of patients with clinical data during the study look-back period of 
9/30/2017 to 9/30/2018 are described below (Table 5). It is possible that a patient was not lost to 
follow-up prior to 9/30/2017 but still had incomplete clinical data, such as a small number or 
lack of UAs from which to derive our proportion measure, during the look-back period. I 
included all relevant data for all patients despite this possibility. According to bivariate analysis, 
there were significant differences between the treatment and control groups for both type of 
OUD treatment and proportion of positive UAs for non-prescribed benzodiazepines and cocaine. 
A greater percentage of patients in the treatment group were treated with buprenorphine; 13.6% 
of the treatment group compared to 3.7% of the control group. The mean value for proportion of 
positive UAs for non-prescribed benzodiazepines and cocaine was 0.2 (±0.3) for the treatment 
group and 0.3 (±0.4) for the control group; this difference was significant at p=0.011.   
 
Table 5. Clinical indicators according to HCV treatment status from medical chart review 
9/30/2017 to 9/30/2018a, b 
 HCV Treatment   
Variable Treatment (N=66) Control (N=135) Pc   
OUD Treatment    0.009 
     Methadone  57 (86.4) 130 (96.3)  
     Buprenorphine 9 (13.6) 5 (3.7)  
Urine analysis (Proportion positive)    
Non-prescribed opioids  0.2 (±0.3) 0.2 (± 0.3) 0.361 
Non-prescribed benzodiazepines 
and cocaine   0.2 (± 0.3) 0.3 (± 0.4) 0.011 
Prescription validation    
     Opioids   0.079 
          Yes 8 (12.1) 7 (5.2)  
          No  58 (87.9) 128 (94.8)  
Benzodiazepines    0.365 
     Yes 12 (18.2) 18 (13.3)  
     No  54 (81.8) 117 (86.7)  
Counseling Beyond Requirements 42 (63.6) 79 (58.5) 0.486 
Psychiatric Services Use  22 (33.3) 28 (20.7) 0.052 
Intensive Outpatient Use  4 (6.1) 9 (6.7) 0.870 
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a Table values are mean ± SD for continuous variables and n (column %) for categorical variables 
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to 
rounding 
c P-value is for t-test (continuous variables) or χ2 test (categorical variables) 
 
 As described by Table 5, there was not a significant difference according to bivariate 
analysis between the treatment and control groups for the proportion of positive UA results for 
non-prescribed opioids over the 12-month study look-back period. HCV treatment providers at 
APT Foundation, however, had an a priori assumption based on clinical experiences that patients 
in the treatment group would be less likely to have ongoing illicit opioid use. Thus, I attempted 
to conduct a linear regression using proportion of positive UAs for non-prescribed opioids. To 
increase the interpretability of the data, I decided to categorize the outcome variable into 
quartiles and then completed an ordered logistic regression. Bivariate analysis of the categorized 
UA proportions according to HCV treatment is represented in Table 6.  
 
Table 6. Bivariate analysis with categorized proportion of positive urine analysis results for non-
prescribed opioids from 9/30/2017 to 9/30/2018a, b  
 
 HCV Treatment   
Variable Treatment (N=66) Control (N=132) Pc   
Proportion positive urine analyses 
for non-prescribed opioids    0.603 
     < 25%  48 (72.7) 92 (69.7)  
     25-49% 10 (15.2) 15 (11.4)  
     50-74%  4 (6.1) 11 (8.3)  
≥ 75%  4 (6.1) 14 (10.6)  
a Table values are n (row %)  
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to 
rounding 
c P-value is for χ2 test 
  
 Results from the ordered logistic regression with the outcome as categorized proportions 
of positive UA results for non-prescribed opioids do not indicate a positive significant difference 
between the treatment and control groups. In the unadjusted model, patients in the treatment 
 
Severe 26 
group have 1.2 (95%CI, 0.7 to 2.4) increased likelihood of having a lower category of positive 
UA results for non-prescribed opioids compared to the control group. After including all 
covariates – the original baseline covariates according to earliest BASIS-24 date in the study 
period as well as all of the clinical covariates collected in chart review – the treatment group had 
0.5 (95%CI, 0.2 to 1.3) increased likelihood of having a lower category of positive UA results 
for non-prescribed opioids compared to the control group. I did not arrive at a model in which 
there was a significant association between treatment and control groups for this outcome 
variable even after using stepwise elimination of non-significant covariates. The model was also 
not significant when only baseline characteristics (i.e., the baseline BASIS-24 survey results with 
demographic information) were included in the model. I also transformed the outcome variable 
to be dichotomous (greater or less than 50%); using this as the outcome variable in a simple 
logistic regression did not produce a significant difference between the treatment and control 
groups.  
 Interestingly, the only significant predictor variable in the logistic regression described 
above was the proportion of positive UAs for non-prescribed benzodiazepines and cocaine. 
Based on this finding, I conducted an exploratory analysis using the proportion of non-prescribed 
benzodiazepines and cocaine as an outcome variable. I first categorized the variable into 
quartiles, and conducted bivariate analysis (Table 7). Using an ordered logistic regression, the 
unadjusted association found that patients in the treatment group had 1.9 (95%CI, 1.0 to 3.4) 
increased likelihood of having a lower category of positive UAs for non-prescribed 
benzodiazepines and cocaine compared to the control group; this association was significant at 
p=0.040. The adjusted association that included all covariates, including the proportion of 
positive UAs for non-prescribed opioids, was also significant. According to the adjusted 
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analysis, patients in the treatment group had 3.0 (95%CI, 1.2 to 7.4) increased likelihood of 
having a lower category of positive UAs for non-prescribed benzodiazepines and cocaine 
compared to the control group; this was significant at p=0.019. Though this was an exploratory 
analysis, these results indicate that a decreased presence of other substances (like non-prescribed 
benzodiazepines and cocaine) may be a potential outcome after a patient is treated with HCV 
treatment. This will be further discussed in the subsequent section.  
 
Table 7. Bivariate analysis with categorized proportion of positive urine analysis results for non-
prescribed benzodiazepines and cocaine from 9/30/2017 to 9/30/2018a, b  
 
 HCV Treatment   
Variable Treatment (N=66) Control (N=132) Pc   
Proportion positive urine analyses 
for non-prescribed benzodiazepines 
and cocaine     0.081 
     < 25%  43 (65.2) 70 (53.0)  
     25-49% 11 (16.7) 15 (11.4)  
     50-74%  5 (7.6) 16 (12.1)  
≥ 75%  7 (10.6) 31 (23.5)  
a Table values are n (row %)  
b Numbers may not sum to total due to missing data, and percentages may not sum to 100% due to 
rounding 
c P-value is for χ2 test 
 
Change in BASIS-24 Scores  
 The final outcome measure for this study was the change in BASIS-24 scores over the 
time of the study period (1/1/2014 to 9/30/2018). For the “post” BASIS-24 survey result date, as 
described, I used the survey date that was closest to the last day of the study period (9/30/2018) 
for patients in the treatment and control groups. See Table 2 for baseline BASIS-24 survey 
results and recall that, in bivariate analysis, scores for depression/functioning and self-harm were 
both positively significant for the treatment as compared to the control group. Table 8 
demonstrates the same bivariate analyses but using BASIS-24 scores closest to the conclusion of 
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the study period. In the “post” period, I observed positive significant differences for 
depression/functioning, emotional lability, substance use, and overall scores. Patients in the 
treatment group, for example, scored a mean of 1.1 (±0.9) for depression/functioning while 
patients in the control group scored a mean of 1.4 (±1.0) for the same measure; this was highly 
significant at p=0.008.  
 
Table 8. Follow-up behavior and symptom indicators according to HCV treatment status using 
most recent to 9/30/2018 BASIS-24 survey results a 
 
  HCV Treatment   
Sub-scales and overall scores Treatment (N = 89)  Control (N=199) Pb   
Depression/functioning 1.1 (± 0.9) 1.4 (± 1.0) 0.008 
Relationships 1.8 (± 1.2) 1.7 (± 1.1) 0.620 
Self-Harm 0.2 (± 0.5) 0.2 (± 0.5) 0.345 
Emotional lability 1.1 (± 0.9) 1.4 (± 1.0) 0.025 
Psychosis 0.4 (±0.6)  0.5 (± 0.8) 0.178 
Substance abusec 1.2 (± 1.1) 1.5 (± 1.1) 0.018 
Overall  1.0 (± 0.7) 1.2 (± 0.8) 0.043 
a Table values are mean ± SD  
b P-value is for t-test 
c BASIS-24 survey instrument uses this terminology, which has been removed according to the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition (DSM-5)  
 
I completed analysis on the difference in differences for the BASIS-24 survey results of 
the treatment and control groups from the “pre” to the “post” periods. As demonstrated in Table 
9, I observed a significant difference between the treatment and control groups only for the sub-
score of self-harm. Patients in the treatment group had a mean difference of -0.0 (±0.5) while 
patients in the control group had a mean difference of -0.2 (±0.6); this was significant at 
p=0.031. It appears that the significant difference observed in the self-harm score reflects greater 
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improvement in the control group, contrary to our study hypothesis of seeing improved 
differences of BASIS-24 scores for the treatment group over time.  
 
Table 9. Change in behavior and symptom indicators according to HCV treatment status using 
BASIS-24 survey results closest following 1/1/2014 and most recent to 9/30/2018 a 
 
  HCV Treatment   
Sub-scales and overall scores Treatment (N = 89)  Control (N=199) Pb   
Δ Depression/functioning -0.2 (± 1.0) -0.3 (± 1.0) 0.557 
Δ Relationships -0.0 (± 1.4) -0.0 (± 1.1) 0.912 
Δ Self Harm -0.0 (± 0.5) -0.2 (± 0.6) 0.031 
Δ Emotional lability -0.3 (± 0.9) -0.2 (± 1.1) 0.399 
Δ Psychosis -0.1 (±0.5)  0.0 (± 0.7) 0.190 
Δ Substance abusec  -0.5 (± 1.4) -0.4 (± 1.1) 0.481 
Δ Overall  -0.2 (± 0.7) -0.2 (± 0.7) 0.968 
a Table values are mean ± SD  
b P-value is for t-test 
c BASIS-24 survey instrument uses this terminology, which has been removed according to the Diagnostic 
and Statistical Manual of Mental Disorders, 5th edition (DSM-5)  
  
 Finally, I attempted to conduct a linear regression with the outcome variable as the 
difference in the overall score between the “pre” and “post” BASIS-24 scores according to HCV 
treatment status. However, when testing for normality of the difference overall variable, it did 
not meet the Shapiro-Wilk statistical test for normality. I do not believe that categorizing this 
variable in order to perform a logistic regression would be clinically meaningful, as the negative 
differences are not easily interpreted for practical purposes. I will discuss limitations of this 








Limitations   
 The data in this study – including all documentation of patients with ICD code B18.2, 
patient loss to follow-up dates, and BASIS-24 data –were not originally collected for the purpose 
of a research study but rather for clinical and reporting purposes internal to the APT Foundation. 
Though the APT Foundation and its clinical and research staff contribute to academic research in 
meaningful ways, the primary purpose of the organization is to meet the medical, psychiatric, 
and social needs of its patients. Therefore, the community-level data derived for this study is 
subject to limitations given that research protocols did not prospectively guide the collection and 
organization of the data. Nevertheless, the data used for this study represent realistic conditions 
of a comprehensive OTP in which primary care services, including the treatment of chronic 
HCV, are integrated.  
 The data derived from my chart review process, though it was designed for this research 
study and developed with the input of APT Foundation leadership and staff, are also subject to 
limitations given that only one researcher conducted the chart review. There is the possibility of 
human error in collecting the variables for the chart review. Specifically, for example, it is 
possible that I missed a prescription validation for either synthetic opioids and/or 
benzodiazepines and therefore did not factor this into the calculation of proportion positive urine 
drug analysis results for either variable. It is also possible that the prescription validations for 
either synthetic opioids and/or benzodiazepines were not documented in the chart during the 
study period and thus were not included and/or factored into the calculation of proportion of 
positive results. Indeed, for all variables included in the chart review, the study is limited by 
placing an arbitrary look-back period (9/30/2017 to 9/30/2018) on the capture of these variables. 
 
Severe 31 
I decided upon the look-back period, however, given the 12-week separation of time with the 
conclusion of the HCV treatment period (7/8/2017) as well as my timing of the chart review data 
collection.  
 An additional limitation concerning the collection of clinical data from medical charts is 
that it may have been advantageous for the purpose of our study to collect data from a period 
prior to the beginning of the study period for all patients. This would have allowed for the 
comparison of our secondary outcome variable, proportion of positive UAs for non-prescribed 
opioids, throughout the entire study period. It also may have allowed for the adjustment of 
regression models with the baseline covariates included in the chart review (e.g., proportion of 
positive UAs for non-prescribed benzodiazepines and cocaine, use of psychiatric services). 
Future studies seeking to analyze OUD outcomes among persons treated for HCV while being 
treated with OAT should incorporate such baseline covariates.  
 Studies of HCV infection all must address the inherent challenges in researching this 
infection given its natural history. I compared patients who initiated and completed treatment for 
chronic HCV infection, with patients who had a documented ICD10 code 18.2 and, according to 
chart review, had not been treated previously, elsewhere, or during the study period at the APT 
Foundation for chronic HCV infection. The inclusion and exclusion criteria I applied to the data, 
in addition to limiting our sample sizes for the treatment and control groups, also present several 
limitations. As in the collection of covariates, the chart review process is subject to human error 
and therefore it is possible that I failed to exclude certain patients in our control group who had 
been treated for chronic HCV. It is also possible that a patient could have opted out of initial 
HCV antibody testing during the intake process into the OTP but gone on to develop chronic 
infection during the study period. The patient as well as APT Foundation clinicians would, then, 
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not be aware of infection status. Though this is not specifically a limitation of the current study, I 
am aware that there are patients in the general OTP patient population who may have HCV 
infection but are not included in the data set of patients with documented ICD codes for B18.2. It 
is also possible that I included patients in our control group who had positive HCV antibody 
results and were HCV treatment naïve but had not developed chronic infection that would benefit 
from DAA treatment. Due to the nature of the study setting, however, I decided that ICD B18.2 
coding and a stringent chart review to remove patients who had previously been treated for 
chronic HCV was sufficient for the purpose of this study. 
 The measurement of retention in the present study is also limited given that, though it is 
possible for patients in the sample to have multiple treatment episodes during the time period, I 
was provided with one patient loss to follow-up date per patient, if applicable. I was also not 
provided any information about the reasons for patient loss to follow-up. Though this 
information would contribute to understanding about patient retention in an OTP, it was not 
needed for the purpose of this study. I was concerned only with patient status at the conclusion of 
the study period (9/30/2018). For clinicians and staff at the OTP, a patient’s status as retained in 
the OTP – rather than information about their loss to follow-up – is arguably more crucial 
information in the management of OUD and ancillary services in an OTP.  
 A final set of limitations concerns the BASIS-24 survey results. Due to the nature of the 
study sample and the setting in which it occurred, it is possible that patients have incomplete 
BASIS-24 data. As noted, it is possible that patients have incomplete BASIS-24 results, or 
results that do not adhere to the timeline which APT Foundation sets for the completion of such 
surveys, due to the possibility that patients may have multiple treatment episodes during the 
study period. It is also possible that patients have only one BASIS-24 score throughout the study 
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period, making a comparison of “pre” and “post” BASIS-24 results unfeasible. Among all 
patients included in the study and after removing all BASIS data with missing dates and/or dates 
from the time period prior to 1/1/14, there were approximately 51 unique patients with only one 
BASIS score. This calls into question the internal validity of using the pre/post analysis. It does 
not, however, affect the use of the BASIS survey data as baseline covariates in the above 
analyses. In addition, I selected BASIS-24 dates of completion according to the confines of my 
arbitrary study period and it may have been advantageous to select them based upon the 
treatment group’s HCV treatment dates (i.e., start and end of treatment, date of SVR12). I 
ultimately did not select such dates to align with the selection of BASIS-24 completion dates 
because of the difficulty in matching similar control group times. More complex statistical 
methods would be required in a future study to accomplish that aim.  
 
Discussion 
 There are several key distinctions between the present study and other studies related to 
the treatment of chronic HCV infection among a population of persons who concurrently receive 
OAT for OUD. The first and central difference is that my study does not seek to understand why 
patients do and do not initiate treatment for chronic HCV infection. The outcomes I analyzed in 
our study – retention in care in an OTP, proportion of positive urine drug analyses for non-
prescribed opioids, and change in behavior and symptom indicators – do not allow me to 
speculate on reasons why patients with chronic HCV infection did or did not initiate HCV 
treatment with DAAs. Though I had baseline demographic data prior to the initiation of 
treatment for both groups, I did not use these covariates to model the outcome of HCV treatment. 
I therefore cannot speculate on predictors of whether or not a patient who initiates or completes 
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HCV treatment. Such an endeavor may be best suited first for qualitative inquiry, and the work 
of Wright and colleagues in the Australian context provides an excellent recent example.13 
Anecdotally, from the process of chart review in the present study, I note that clinicians who 
regularly engage with these patients may also be a source of information for qualitative inquiry 
on this topic. Clinicians may provide insights on their own attitudes regarding the counseling of 
patients about HCV treatment, and about common barriers that their patients encounter when 
deciding whether or not to initiate HCV treatment. This research question, though not my own, is 
of utmost importance to those working at the intersection of drug use and HCV infection, as 
increased HCV treatment among this population could help to restrain rising rates of infection.25 
 The second distinction between this and other similar studies is that I do not include SVR 
12 as a study outcome. It has been established that patients who receive HCV treatment 
concurrently with OAT can achieve SVR 12 rates similar to a general patient population. I 
sought to understand how co-located treatment can affect other clinical outcomes. The present 
study demonstrated that, after adjusting for all baseline covariates, patients who undergo and 
complete HCV treatment have 2.2 (95% CI, 1.1 to 4.5) increased likelihood of remaining in the 
OTP compared to patients in the control group. My analysis also showed that, when using the 
dates of loss to follow-up of the treatment and control groups, those treated for chronic HCV 
infection have a significantly higher probability of not being lost to follow-up from the OTP 
compared to the control group. Remaining in the OTP allows a patient to continue his/her OAT 
and, if needed, receive counseling support and psychiatric services, and attend to other medical 
concerns in primary care. There is also recent evidence that, in a Canadian sample of PWID who 
had been treated for HCV infection and who received OAT daily, there was a non-significant 
reduction in the risk of HCV reinfection at 52 weeks post SVR 12.26 A major concern among 
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state Medicaid programs and other insurance payers, given the high (though declining) cost of 
treatment, is the risk of reinfection among patients treated with DAAs.27 This is especially true 
for patients treated with DAAs who also inject drugs and/or receive treatment for OUD in the 
form of opioid agonists. Though further studies are needed, the use of a co-located model of 
treatment for both OUD and HCV may be an effective way of retaining patients in care for OUD 
– which could thereby reduce the risk of HCV reinfection and help the patient to manage his/her 
OUD.  
 A final consideration concerns my findings regarding the outcome of proportion positive 
urine drug analysis results for non-prescribed opioids. In the analyses I conducted, I found that 
patients in the treatment group did not have significantly greater odds of having lower 
proportions of positive UAs for non-prescribed opioids over a 12-month period. The analysis of 
such an outcome for the treatment of OUD with opioid agonists has been accomplished in 
similar ways previously, though not to my knowledge in the context of those being concurrently 
treated for chronic HCV.28 As the treatment of OUD is conceptualized by many in the addiction 
medicine field as the treatment of a chronic illness with accompanying natural fluctuations, it 
may not be appropriate and/or useful to measure proportion of positive UAs for non-prescribed 
opioids as outcome variable of OUD treatment. The use of other illicit substances while 
receiving treatment with opioid agonists is an emerging field of study.29 I included a 
measurement of positive UAs for non-prescribed benzodiazepines and cocaine as a covariate in 
the study. Though this was not a hypothesized outcome for the present study, I conducted an 
exploratory analysis in which this covariate was the outcome of interest with the primary 
predictor variable of HCV treatment. Results demonstrated that patients who were treated for 
HCV had significantly greater odds of having lower proportions of positive UAs for non-
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prescribed benzodiazepines and cocaine, even after adjusting for all baseline covariates. This 
could potentially suggest that, among patients receiving concurrent OAT, the time period 
following HCV treatment could reduce the practice of use of non-prescribed benzodiazepines 
and cocaine. This result is limited, however, because it only reflects a 12-month period following 
treatment; in addition, I combined non-prescribed benzodiazepines and cocaine into one variable 
whereas they may have been better suited as two variables. The results of this exploratory 
analysis require further investigation in future, prospective studies on the effects of HCV 
treatment within a co-located model of care with treatment for OUD.    
 Although this study is limited in ways described above, I demonstrated that HCV 
treatment among patients receiving concurrent treatment for OUD has positive effects on 
retention in an OTP. Ultimately, additional baseline covariates and/or qualitative interviews of 
patients at baseline (i.e., prior to HCV treatment) are needed to generate definitive evidence 
about what mechanisms are involved in accounting for the longer retention in the OTP, as well 
as what patient characteristics and/or practices predict greater retention after completing HCV 
treatment. As noted, further research into the role of non-opioid substances on both HCV and 
OUD treatment outcomes is required for this patient population. A co-located model of care for 
patients in treatment for chronic HCV and OUD can be a highly effective mechanism not only 
for curing one’s HCV infection, but also for continuing on in the management of one’s addiction 
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